Literature DB >> 10220834

Anti-IL-8 autoantibodies and complexes in rheumatoid arthritis: polyclonal activation in chronic synovial tissue inflammation.

P Peichl1, E Pursch, H Bröll, I J Lindley.   

Abstract

The chemokine interleukin-8 (IL-8) is frequently associated with inflammatory diseases, and autoantibodies against IL-8 are present in the periphery at elevated levels in such conditions as rheumatoid arthritis (RA). Circulating free anti-IL-8 IgG autoantibodies correlate with inflammatory parameters and disease severity in RA. In this study, correlations were sought between these disease parameters and other antibody subclasses. We assayed IgM, IgA and IgG anti-IL-8 antibodies and IL-8 immunoglobulin immune complexes in the serum of 29 healthy controls and 56 patients with defined RA, and compared the results with clinical and humoral disease parameters. IgG and IgM antibodies directed against IL-8 were present in all samples. In the disease groups, all isotypes of free anti-IL-8 antibodies correlated with increasing humoral disease parameters like CRP and CIC and their related anti-IL-8 immune complexes. Samples which contained high titers of anti-IL-8 antibody subclasses and complexes were RF subclass-positive, while IgM RF-negative sera showed low levels of anti-IL-8 and complexes. Detectable levels of IgG and IgA RF were found in all sera. Patients with extra-articular organ manifestation showed significantly increased free IgA and IgA/IL-8 complexes, with no correlation to the IgA RF titer or IgA hypergamma-globulinemia. The highest titers were seen in two RA cases with vasculitis and in one patient with colitis. Polyclonal activation of the humoral antibody system, which normally precedes the resolution of an inflammatory response, can itself lead to secondary stimulation of inflammatory processes via immune complex formation. In the immune pathology of RA, it degenerates into a persistent chronic inflammation accompanied by progressive joint destruction. The presence of elevated IgA subclass anti-IL-8 autoantibodies in RA patients with extra-articular manifestations suggests these autoantibodies as a clinically useful marker of disease severity and extra-articular manifestations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10220834     DOI: 10.1007/s002960050073

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  6 in total

1.  Anti-cytokine autoantibodies in autoimmune diseases.

Authors:  Giuseppe Cappellano; Elisabetta Orilieri; Abiy D Woldetsadik; Elena Boggio; Maria F Soluri; Cristoforo Comi; Daniele Sblattero; Annalisa Chiocchetti; Umberto Dianzani
Journal:  Am J Clin Exp Immunol       Date:  2012-11-15

2.  Expression and function of wingless and frizzled homologs in rheumatoid arthritis.

Authors:  M Sen; K Lauterbach; H El-Gabalawy; G S Firestein; M Corr; D A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

3.  Autoantibodies against interleukin-21 correlate with disease activity in patients with rheumatoid arthritis.

Authors:  Rui Xing; Lin Sun; Dong Wu; Yinji Jin; Changhong Li; Xiangyuan Liu; Jinxia Zhao
Journal:  Clin Rheumatol       Date:  2017-10-10       Impact factor: 2.980

4.  The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8).

Authors:  M C Kraan; D D Patel; J J Haringman; M D Smith; H Weedon; M J Ahern; F C Breedveld; P P Tak
Journal:  Arthritis Res       Date:  2000-11-09

Review 5.  The Role of GM-CSF Autoantibodies in Infection and Autoimmune Pulmonary Alveolar Proteinosis: A Concise Review.

Authors:  Ali Ataya; Vijaya Knight; Brenna C Carey; Elinor Lee; Elizabeth J Tarling; Tisha Wang
Journal:  Front Immunol       Date:  2021-11-22       Impact factor: 7.561

6.  Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens.

Authors:  Gözde Isik; Thijs van Montfort; Nancy P Y Chung; John P Moore; Rogier W Sanders
Journal:  J Immunol       Date:  2014-04-11       Impact factor: 5.422

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.